繁體版 / 簡體版
 
R&D PORTFOLIO
/ SNP-630

SNP-630

Indication
Non-alcoholic steatohepatitis (NASH)
Product Advantages
1. Optimized New Chemical Entity
2. First-in-class
3. For NASH and ASH
Status
1. Pre-clinical
2. SNP-630 and/or its active metabolites: some human experience
3. Plan to apply US FDA IND, fast track and breakthrough designation
Competitive Edge
1. Multiple mechanisms of action
2. Direct action on liver
3. Optimal potency
4. Great safety profile
Potential Market
The estimated global market for NASH: 35-40 B per year

Multiple Mechanisms of Action of SNP-6xx


体彩p5中奖新闻 云南时时彩论坛 广西快3和值遗漏 万豪娱乐游戏城官网 福建十一选五一定牛 怎么看个股票指数 上海快三怎么玩的 时时彩四星中奖条件 大智慧模拟炒股下载 王中王开奖结果查询 吉林11选5玩法技巧